New-Onset Refractory Status Epilepticus (NORSE): The Queen Square Neuro-ICU experience
•We found no difference in outcome between those with NORSE and non-NORSE SE.•Similarly there were no differences in the sub-group analysis of the NORSE cohort.•This raises questions as to the clinical utility and validity of the term ‘NORSE’. The introduction and widespread adoption of the term ‘NO...
Gespeichert in:
Veröffentlicht in: | Epilepsy & behavior 2021-12, Vol.125, p.108387-108387, Article 108387 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •We found no difference in outcome between those with NORSE and non-NORSE SE.•Similarly there were no differences in the sub-group analysis of the NORSE cohort.•This raises questions as to the clinical utility and validity of the term ‘NORSE’.
The introduction and widespread adoption of the term ‘NORSE’ – new-onset refractory status epilepticus – raises both fundamental conceptual and pragmatic questions. We studied a cohort of patients with ‘NORSE’ at the National Hospital for Neurology and Neurosurgery to investigate the clinical features, treatment responses, and outcomes with a focus on sub-group analysis. We identified 26 cases of ‘NORSE’. There was no difference in prognosis between ‘NORSE’ and non-‘NORSE’ RSE, nor in any sub-analysis in the ‘NORSE’ cohort. We discuss the utility and validity of the term NORSE as a descriptor for a subgroup with RSE in whom the underlying etiologies are heterogeneous and pathophysiological mechanisms are unknown. |
---|---|
ISSN: | 1525-5050 1525-5069 |
DOI: | 10.1016/j.yebeh.2021.108387 |